Noninvasive optical screening for diabetes.
BACKGROUND
Advanced glycation end products (AGEs) are implicated in the complications of diabetes. Advanced glycation end products also accumulate in the skin and are sensitive biomarkers for the risk of developing diabetes and related complications. Some AGEs fluoresce and can be measured noninvasively by optical spectroscopy.


METHODS
Noninvasive screening for diabetes has been evaluated in an 18-site study involving a cohort of 2793 subjects meeting American Diabetes Association-based screening criteria. Subjects were measured with a specialized skin fluorimeter and also received traditional blood glucose and glycated hemoglobin tests.


RESULTS
Retrospective results indicated that the noninvasive technology measuring dermal fluorescence is more sensitive at detecting abnormal glucose tolerance than either fasting plasma glucose or glycated hemoglobin A1C.


CONCLUSIONS
These results suggest that noninvasive measurement of dermal fluorescence may be an effective tool to identify individuals at risk for diabetes and its complications. The noninvasive technology yields immediate results, and since measuring dermal fluorescence requires no blood draws or patient fasting, the instrument may be well suited for opportunistic screening.
Ediger
Marwood N
MN
VeraLight, Inc., Albuquerque, New Mexico87106, USA. woody.ediger@veralight.com
Olson
Byron P
BP
Maynard
John D
JD
D003920:Diabetes Mellitus / Q000175:diagnosis*; D005260:Female; D005470:Fluorometry; D017127:Glycation End Products, Advanced; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D012867:Skin
D017127:Glycation End Products, Advanced